Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations

References

• Cooper S, Spiro SG. (2006). Small cell lung cancer: treatment review. Respirology, 11:241–248.
   PubMed Web of Science ®Google Scholar
• Tomoda K, Ohkoshi T, Hirota K, Sonavane GS, Nakajima T, Terada H et al. (2009). Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B Biointerfaces, 71:177–182.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Lichtman AH, Pober JS. (2000). Cellular and Molecular Immunology. Saunders Company, Boulder, CO.
   Google Scholar
• Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA et al. (1990). Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol, 8:1650–1656.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS et al. (1994). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst, 86:1159–1166.
   PubMed Web of Science ®Google Scholar
• Physicians’ Desk Reference (PDR), 61st ed. (2007). Thomson PDR, Montvale.
   Google Scholar
• Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS. (1997). Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer, 79:1409–1421.
   PubMed Web of Science ®Google Scholar
• Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV et al. (2008). Local therapy of cancer with free IL-2. Cancer Immunol Immunother, 57:931–950.
   PubMed Web of Science ®Google Scholar
• Bernsen MR, Tang JW, Everse LA, Koten JW, Otter WD. (1999). Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Cancer Treat Rev, 25:73–82.
   PubMed Web of Science ®Google Scholar
• Mallol J, Robertson CF, Cook D, Kaymakci B. (1997). Nebulized gentamicin in children with cystic fibrosis: enhancing antibiotic lung deposition by increasing flow rate and fill volume. J Aersol Med, 10:331–340.
   Google Scholar
• Georgitis JW. (1999). The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. National Heart, Lung, and Blood Institute. Chest, 115:210–217.
   PubMed Web of Science ®Google Scholar
• Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. (1995). Inhalation of antibiotics in cystic fibrosis. Eur Respir J, 8:1594–1604.
   PubMed Web of Science ®Google Scholar
• Newhouse MT, Corkery KJ. (2001). Aerosols for systemic delivery of macromolecules. Respir Care Clin N Am, 7:261–75, vi.
   PubMedGoogle Scholar
• Timsina MP, Martin GP, Marriott C, Ganderton D, Yainneskis M. (1994). Drug delivey to the respiratory tract using dry powder inhalers. Int J Pharm, 101:1–13.
   Web of Science ®Google Scholar
• Todo H, Okamoto H, Iida K, Danjo K. (2001). Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int J Pharm, 220:101–110.
   PubMed Web of Science ®Google Scholar
• Telko MJ, Hickey AJ. (2005). Dry powder inhaler formulation. Respir Care, 50:1209–1227.
   PubMedGoogle Scholar
• Hickey AJ, Martonen TB, Yang Y. (1996). Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Pharm Acta Helv, 71:185–190.
   PubMedGoogle Scholar
• Tolman JA, Williams RO III. (2010). Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Dev Ind Pharm, 36:1–30.
   PubMed Web of Science ®Google Scholar
• Gilani K, Najafabadi AR, Barghi M, Rafiee-Tehrani M. (2005). The effect of water to ethanol feed ratio on physical properties and aerosolization behavior of spray dried cromolyn sodium particles. J Pharm Sci, 94:1048–1059.
   PubMed Web of Science ®Google Scholar
• Schiavone H, Palakodaty S, Clark A, York P, Tzannis ST. (2004). Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. Int J Pharm, 281:55–66.
   PubMed Web of Science ®Google Scholar
• Iida K, Hayakawa Y, Okamoto H, Danjo K, Leuenberger H. (2001). Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier. Chem Pharm Bull, 49:1326–1330.
   PubMed Web of Science ®Google Scholar
• Learoyd TP, Burrows JL, French E, Seville PC. (2008). Modified release of beclometasone dipropionate from chitosan-based spray-dried respirable powders. Powder Technol, 187:231–238.
   Web of Science ®Google Scholar
• Steckel H, Bolzen N. (2004). Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm, 270:297–306.
   PubMed Web of Science ®Google Scholar
• Smyth HDC, Hickey AJ. (2005). Carriers in drug powder delivery. Implications for inhalation system design. Am J Drug Deliv, 3:117–132.
   Google Scholar
• Tee SK, Marriott C, Zeng XM, Martin GP. (2000). The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int J Pharm, 208:111–123.
   PubMed Web of Science ®Google Scholar
• Saint-Lorant G, Leterme P, Gayot A, Flament MP. (2007). Influence of carrier on the performance of dry powder inhalers. Int J Pharm, 334:85–91.
   PubMed Web of Science ®Google Scholar
• Kaialy W, Martin GP, Ticehurst MD, Momin MN, Nokhodchi A. (2010). The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient. Int J Pharm, 392:178–188.
   PubMed Web of Science ®Google Scholar
• Devrim B, Bozkır A, Canefe K. (2009). Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of recombinant human interleukin-2 microparticles. 36th Annual & Exposition of the Controlled Release Society, Copenhagen, Denmark, July 18–22.
   Google Scholar
• Devrim B, Bozkır A, Canefe K. (2009). Surface-modified PLGA microparticles as pulmonary delivery vehicles for rhIL-2. Eur J Pharm Sci, 38(Suppl):114–116.
   Google Scholar
• Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ. (2002). Design of biodegradable particles for protein delivery. J Control Release, 78:15–24.
   PubMed Web of Science ®Google Scholar
• Chen H, Yang W, Chen H, Liu L, Gao F, Yang X et al. (2009). Surface modification of mitoxantrone-loaded PLGA nanospheres with chitosan. Colloids Surf B Biointerfaces, 73:212–218.
   PubMed Web of Science ®Google Scholar
• Vladisavljevi´c GT, Schubert H. (2003). Influence of process parameters on droplet size distribution in SPG membrane emulsification and stability of prepared emulsion droplets. J Membr Sci, 225:15–23.
   Web of Science ®Google Scholar
• Meng FT, Ma GH, Qiu W, Su ZG. (2003). W/O/W double emulsion technique using ethyl acetate as organic solvent: effects of its diffusion rate on the characteristics of microparticles. J Control Release, 91:407–416.
   PubMed Web of Science ®Google Scholar
• Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H et al. (2010). Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin. Int J Pharm, 389:74–85.
   PubMed Web of Science ®Google Scholar
• Bosquillon C, Préat V, Vanbever R. (2004). Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Release, 96:233–244.
   PubMed Web of Science ®Google Scholar
• McConville JT, Son Y-J. (2008). Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm, 34:948–959.
   PubMed Web of Science ®Google Scholar
• Rawat A, Majumder QH, Ahsan F. (2008). Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release, 128:224–232.
   PubMed Web of Science ®Google Scholar
• European Pharmacopoiea. (2008). Preparations for Inhalation: Aerodynamic Assessment of Fine Particles, 6th ed. Council of Europe, Strasbourg, France.
   Google Scholar
• Bhavna Ahmad, FJ, Mittal G, Jain GK, Malhotra G, Khar RK et al. (2009). Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm, 71:282–291.
   PubMed Web of Science ®Google Scholar
• Ibrahim BM, Jun SW, Lee MY, Kang SH, Yeo Y. (2010). Development of inhalable dry powder formulation of basic fibroblast growth factor. Int J Pharm, 385:66–72.
   PubMed Web of Science ®Google Scholar
• Watts AB, Cline AM, Saad AR, Johnson SB, Peters JI, Williams RO 3rd. (2010). Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a lung transplanted rodent model. Int J Pharm, 384:46–52.
   PubMed Web of Science ®Google Scholar
• Eskandar F, Lejeune M, Edge S. (2011). Low powder mass filling of dry powder inhalation formulations. Drug Dev Ind Pharm, 37:24–32.
   PubMed Web of Science ®Google Scholar
• Klingler C, Müller BW, Steckel H. (2009). Insulin-micro- and nanoparticles for pulmonary delivery. Int J Pharm, 377:173–179.
   PubMed Web of Science ®Google Scholar
• Trapani G, Lopedota A, Boghetich G, Latrofa A, Franco M, Sanna E et al. (2003). Encapsulation and release of the hypnotic agent zolpidem from biodegradable polymer microparticles containing hydroxypropyl-beta-cyclodextrin. Int J Pharm, 268:47–57.
   PubMed Web of Science ®Google Scholar
• United States Pharmacopoeia 32 National Formulary 27, 2nd supp. (2010). Powder Flow, 1174. Rockville, MD: The United States Pharmacopoeial Convention, Inc.
   Google Scholar
• Sivadas N, O’Rourke D, Tobin A, Buckley V, Ramtoola Z, Kelly JG et al. (2008). A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm, 358:159–167.
   PubMed Web of Science ®Google Scholar
• Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R et al. (1999). Formulation and physical characterization of large porous particles for inhalation. Pharm Res, 16:1735–1742.
   PubMed Web of Science ®Google Scholar
• El-Gendy N, Gorman EM, Munson EJ, Berkland C. (2009). Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci, 98:2731–2746.
   PubMed Web of Science ®Google Scholar